Skip to content
Clinical Trials – home

Schmerzklinik Kiel Gmbh & Co. KG Klinik fuer neurologisch-verhaltensmedizinische Schmerztherapie

Research site

Germany Heikendorfer Weg 9-27, Neumuehlen-Dietrichsdorf, 24149 Kiel, Germany

  • Migraine · Migraine with aura · Migraine without aura
  • Adults and children

About Specializations

Schmerzklinik Kiel Gmbh & Co. KG Klinik fuer neurologisch-verhaltensmedizinische Schmerztherapie in Kiel, Germany specialises in clinical trials of conditions such as Migraine, Migraine with aura, Migraine without aura, Migraine prophylaxis, and other specialisations. This site conducts important research.

Main research areas of the site

Nervous System Diseases and Migraine Research

The Schmerzklinik Kiel Gmbh & Co. KG Klinik fuer neurologisch-verhaltensmedizinische Schmerztherapie is conducting clinical trials focused on nervous system diseases, with a strong emphasis on migraine care. The studies mainly address chronic migraine, episodic migraine, and related migraine patterns, aiming to improve prevention, symptom control, and day-to-day disease management.

  • Testing new preventive options for chronic migraine and episodic migraine
  • Comparing treatments to better understand safety and tolerability in migraine
  • Evaluating therapies for faster relief during migraine attacks

Much of the research at this clinic in Kiel is centered on whether emerging therapies can reduce migraine frequency and improve quality of life for people living with recurring headache disorders.

Migraine Prevention and Treatment Effectiveness

This group of trials explores how well different approaches work in preventing and treating migraine, including both chronic and episodic forms. The research is designed to assess treatment effectiveness, compare options already in use, and identify better ways to reduce the burden of frequent migraine attacks.

  • Preventive treatment studies for chronic migraine
  • Head-to-head comparisons of migraine therapies
  • Studies measuring reductions in monthly migraine days

These trials reflect a practical focus on finding treatments that are not only effective, but also acceptable for long-term use in everyday migraine care.

Acute Migraine Relief and Symptom Control

Another important area of research at the site looks at acute migraine treatment, especially for adults who need fast and reliable relief from migraine pain. The trials are evaluating whether new therapies can improve short-term symptom control and offer an alternative for people who may not be suitable for standard options.

  • Assessing rapid pain relief in migraine
  • Comparing investigational treatment with placebo
  • Supporting better options for patients with migraine attacks with or without aura

By focusing on immediate symptom reduction, this research aims to expand treatment choices for people whose migraines disrupt work, family life, and daily routines.

Advanced Migraine Therapies for Unmet Needs

The site is also involved in studies of newer migraine therapies for people whose symptoms have not responded well to previous preventive treatment. These trials are helping researchers understand whether innovative approaches can offer safer, more effective long-term control of migraine.

  • Investigating new preventive therapies for chronic migraine
  • Studying options for patients with limited response to earlier treatments
  • Evaluating treatment benefit in migraine prevention

This line of research highlights a clear goal: to address persistent migraine symptoms with therapies that may better meet the needs of patients who still struggle despite existing care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Heikendorfer Weg 9-27, Neumuehlen-Dietrichsdorf24149 KielGermany
Recruiting now
no trials
Conditions studied
4

More sites in KielGermany

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Condition
Type of trial
Recruitment status
Quick filters

9 clinical trials

Migraine

Not recruiting

Study of IncobotulinumtoxinA injections compared to placebo for prevention of episodic migraine attacks

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Merz Therapeutics GmbH

Migraine

Not recruiting

Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Merz Therapeutics GmbH

Migraine

Not recruiting

Study of IPN10200 compared to placebo for prevention of episodic or chronic migraine in adults

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
  • Sponsor:Ipsen Innovation

Migraine

Not recruiting

Study on Lu AG09222 for Preventing Migraines in Adults Unresponsive to Previous Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Lu Ag09222
  • Sponsor:H. Lundbeck A/S

Migraine

Not recruiting

Study of Erenumab Compared to Placebo for Children and Adolescents with Episodic Migraine to Reduce Monthly Migraine Days

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Erenumab
  • Sponsor:Amgen Inc.

Migraine

Not recruiting

A Study of Erenumab Compared to Placebo for Children and Teenagers With Chronic Migraine to Test How Well It Works and How Safe It Is

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Erenumab
  • Sponsor:Amgen Inc.

Migraine

Not recruiting

Study on Rimegepant for Treating Migraine in Adults Who Cannot Use Triptans

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rimegepant
  • Sponsor:Pfizer Inc.

Migraine+3

Not recruiting

Study Comparing Atogepant and Topiramate for Preventive Treatment in Adults with Migraine

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Migraine+2

Not recruiting

Study on Long-Term Safety of Atogepant for Preventing Migraine in Patients with Chronic or Episodic Migraine

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.